CN106619688A - Pharmaceutical composition for treating diabetes and application - Google Patents
Pharmaceutical composition for treating diabetes and application Download PDFInfo
- Publication number
- CN106619688A CN106619688A CN201611229706.0A CN201611229706A CN106619688A CN 106619688 A CN106619688 A CN 106619688A CN 201611229706 A CN201611229706 A CN 201611229706A CN 106619688 A CN106619688 A CN 106619688A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- diabetes
- histidine
- coixol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses pharmaceutical composition for treating diabetes and an application. The pharmaceutical composition is prepared from active components in parts by mass as follows: L-histidine, 11-14 parts of coixol and 16-20 parts of gemcitabine hydrochloride; the administration dosage is 0.54 mg active components/kg/d for adults. The pharmaceutical composition has the effects of nourishing the kidney, nourishing yin and lowering blood glucose. Clinical test results indicate that the pharmaceutical composition has the advantages of being significant and reliable in curative effect, safe and free of adverse reactions and toxic and side effects and is applicable to clinical treatment of the diabetes.
Description
Technical field
The present invention relates to Western medicine field, specifically a kind of pharmaceutical composition for treating diabetes and application.
Background technology
Diabetes are one group of metabolic diseases being characterized with hyperglycaemia.Hyperglycaemia be then due to defect of insulin secretion or
Its biological agent is damaged, or both have concurrently and cause.Long-standing hyperglycaemia during diabetes, cause various tissues, particularly eye,
Kidney, heart, blood vessel, chronic lesion, the dysfunction of nerve.
Diabetes are also called diabete, and the traditional Chinese medical science thinks that its origin cause of formation is more due to overfeeding delicious food, eating and drinking without temperance, inadequate natural endowment, element
Body yin deficiency, or give up completely to natural impulse, disorder of emotion, or internal lesion caused by overexertion excessively cause yin jin loss, scorching, more damage yin jin, the two each other because
Really.With blood as body, with gas as use, liver controlling conveyance and dispersion adjusts human physiological functions to liver, and irritability catharsis is then happy, and qi and blood is put down
With strongly fragrant and change fire if depressed emotion or rage impairing liver, then liquid is hindered in Tianjin of burning, and viscera function is disorderly, so as to cause diabetes.
At present, that prevents and treats diabetes it is critical only that holding blood sugar steadily and the control to its complication.The side of control blood sugar
Method is not simple treatment, is less simple drug therapy, but proposes control diabetes according to the World Health Organization (WHO)
Five-term measure, i.e. diet control, kinesiatrics, drug therapy, diabetes education, blood sugar monitoring carry out integrated control.Wherein, medicine
Thing treatment is the key for controlling blood sugar.Although chemical sugar-lowering medicine can control to a certain extent hyperglycaemia, due to the poison of itself
The organs such as side effect, liver, kidney, the heart, brain to human body cause serious infringement, increase the development of complication.
The content of the invention
It is an object of the invention to provide a kind of evident in efficacy, pharmaceutical composition for the treatment of diabetes for having no toxic side effect and
Using.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition is by following mass fraction meter
L-histidine 1.2-1.7 parts, Coixol 11-14 parts, gemcitabine hydrochloride 16-20 parts composition.
As further scheme of the invention：The active component of described pharmaceutical composition by following mass fraction meter a left side
Rotation histidine 1.4-1.6 parts, Coixol 12-13 parts, gemcitabine hydrochloride 17-19 parts composition.
As further scheme of the invention：The active component of described pharmaceutical composition by following mass fraction meter a left side
1.4 parts of histidine of rotation, 13 parts of Coixol, 18 parts of compositions of gemcitabine hydrochloride.
As further scheme of the invention：Adult's dosage of described pharmaceutical composition is that 0.5-0.6mg is active
Composition/kg/ days.
As further scheme of the invention：Adult's dosage of described pharmaceutical composition be 0.54mg activity into
Point/kg/ days.
Application of the described pharmaceutical composition in treatment diabetes medicament is prepared.
Compared with prior art, the invention has the beneficial effects as follows：Pharmaceutical composition of the present invention has nourishing kidney-YIN, reduces blood
Effect of sugar, clinical test results show that the pharmaceutical composition there is reliable, safety evident in efficacy to have no adverse reaction and the secondary work of poison
Advantage, it is adaptable to the clinical treatment of diabetes.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition
It is made up of 1.2 parts of the l-histidine of following mass fraction meter, 14 parts of Coixol, 16 parts of gemcitabine hydrochloride.
Embodiment 2
In the embodiment of the present invention, a kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition
It is made up of 1.7 parts of the l-histidine of following mass fraction meter, 11 parts of Coixol, 20 parts of gemcitabine hydrochloride.
Embodiment 3
In the embodiment of the present invention, a kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition
It is made up of 1.4 parts of the l-histidine of following mass fraction meter, 13 parts of Coixol, 17 parts of gemcitabine hydrochloride.
Embodiment 4
In the embodiment of the present invention, a kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition
It is made up of 1.6 parts of the l-histidine of following mass fraction meter, 12 parts of Coixol, 19 parts of gemcitabine hydrochloride.
Embodiment 5
In the embodiment of the present invention, a kind of pharmaceutical composition for treating diabetes, the active component of described pharmaceutical composition
It is made up of 1.4 parts of the l-histidine of following mass fraction meter, 13 parts of Coixol, 18 parts of gemcitabine hydrochloride.
In above-described embodiment, the preparation process of the pharmaceutical composition of described treatment diabetes is：With l-histidine, the heart of a lotus seed
Job's tears element and gemcitabine hydrochloride are active component, using acceptable technique and auxiliary material in pharmacy, are made in various pharmacies
Acceptable peroral dosage form.
Pharmaceutical composition of the present invention has nourishing kidney-YIN, drops hypoglycemic effect.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (6)
1. a kind of pharmaceutical composition for treating diabetes, it is characterised in that the active component of described pharmaceutical composition is by following
L-histidine 1.2-1.7 parts of mass fraction meter, Coixol 11-14 parts, gemcitabine hydrochloride 16-20 parts composition.
2. it is according to claim 1 treatment diabetes pharmaceutical composition, it is characterised in that described pharmaceutical composition
Active component by following mass fraction meter l-histidine 1.4-1.6 parts, Coixol 12-13 parts, gemcitabine hydrochloride 17-19
Part composition.
3. it is according to claim 2 treatment diabetes pharmaceutical composition, it is characterised in that described pharmaceutical composition
Active component is made up of 1.4 parts of the l-histidine of following mass fraction meter, 13 parts of Coixol, 18 parts of gemcitabine hydrochloride.
4. according to the pharmaceutical composition of the arbitrary described treatment diabetes of claim 1-3, it is characterised in that described medicine group
Adult's dosage of compound is 0.5-0.6mg active components/kg/ days.
5. it is according to claim 4 treatment diabetes pharmaceutical composition, it is characterised in that described pharmaceutical composition
Adult's dosage is 0.54mg active components/kg/ days.
6. the application according to the arbitrary described pharmaceutical composition of claim 1-3 in treatment diabetes medicament is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611229706.0A CN106619688A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating diabetes and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611229706.0A CN106619688A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating diabetes and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619688A true CN106619688A (en) | 2017-05-10 |
Family
ID=58831653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611229706.0A Pending CN106619688A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating diabetes and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619688A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506048A (en) * | 2002-12-05 | 2004-06-23 | 上海倍艺医药科技有限公司 | Application of levo histidine in treating diabetes |
| CN1703223A (en) * | 2002-10-09 | 2005-11-30 | 阿斯利康(瑞典)有限公司 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| CN102503907A (en) * | 2011-10-14 | 2012-06-20 | 辽宁仙鹤矿泉水有限公司 | Method for extracting coixol from rhizoma phragmitis |
-
2016
- 2016-12-27 CN CN201611229706.0A patent/CN106619688A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1703223A (en) * | 2002-10-09 | 2005-11-30 | 阿斯利康(瑞典)有限公司 | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| CN1506048A (en) * | 2002-12-05 | 2004-06-23 | 上海倍艺医药科技有限公司 | Application of levo histidine in treating diabetes |
| CN102503907A (en) * | 2011-10-14 | 2012-06-20 | 辽宁仙鹤矿泉水有限公司 | Method for extracting coixol from rhizoma phragmitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harvey et al. | Insulin versus lipid emulsion in a rabbit model of severe propranolol toxicity: a pilot study | |
| US10821126B2 (en) | Agent for treating retinopathy | |
| CN108635511A (en) | Radix Paeoniae Alba and dendrobium candidum are preparing the application process in treating hypertension drug | |
| CN108261505A (en) | A kind of drug of logical stalkization bolt and preparation method thereof | |
| CN106619688A (en) | Pharmaceutical composition for treating diabetes and application | |
| CN104706777A (en) | Traditional Chinese medicine narcotic analgesic for treating hip replacement postoperation pain | |
| CA2806619C (en) | Anti-diabetic compositions and methods | |
| CN104770644A (en) | Diabetes health care product based on affinal drugs and diet | |
| CN106389492A (en) | Chinese and western medicine composition for treating hypertension and preparing method and application thereof | |
| CN101897698A (en) | Sugar-lowering drug composition containing vildagliptin and B vitamins and application thereof | |
| CN106466325B (en) | A kind of drug, composition and its preparation prevented or treat diabetes | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN101347511B (en) | Medicament composition with function for reducing blood sugar | |
| CN105343419A (en) | Traditional Chinese medicinal pill for invigorating yang and tonifying kidney, and preparation method thereof | |
| CN108159030A (en) | Application of the hordenine in hypoglycemic drug is prepared | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN109966494A (en) | A kind of prevention and/or the application in the drug of drug and VEGFR1 inhibitor for the treatment of diabetes | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN103263405B (en) | Medicinal composition for treating diabetes, and its application | |
| Mathur | Insulin resistance and the use of metformin: effect on body weight | |
| CN105832718B (en) | Flavones Sophoraflavanone G are preparing the application in preventing diabetes medicament | |
| CN102091326B (en) | Transdermal medicament delivery preparation for treating hemorrhoid diseases caused by expansion or varix of anal subcutaneous veniplex and preparation method thereof | |
| CN104940193B (en) | A kind of reducing blood lipid hypoglycemic medicament composition and its application containing Simvastatin | |
| CN104997780B (en) | A kind of Rosuvastatin calcium composition and its application in reducing blood lipid hypoglycemic medicament is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |